CYPHERPUNK TECHNOLOGIES INC. (CYPH) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -17.77M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 2.58M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-17.77M | (m) | (m) | $2.58M | (m) | (m) |
| 2026-03-31 | $-29.97M | (m) | (m) | $12.92M | (m) | (m) |
| 2025-12-31 | $-41.07M | (m) | (m) | $25.67M | (m) | (m) |
| 2025-09-30 | $-52.09M | (m) | (m) | $37.81M | (m) | (m) |
| 2025-06-30 | $-66.78M | (m) | (m) | $51.48M | (m) | (m) |
| 2025-03-31 | $-71.15M | (m) | (m) | $58.82M | (m) | (m) |
| 2024-12-31 | $-70.06M | (m) | (m) | $57.21M | (m) | (m) |
| 2024-09-30 | $-68.75M | (m) | (m) | $55.78M | (m) | (m) |
| 2024-06-30 | $-65.73M | (m) | (m) | $52.37M | (m) | (m) |
| 2024-03-31 | $-59.14M | (m) | (m) | $45.59M | (m) | (m) |
| 2023-12-31 | $-87.04M | (m) | (m) | $73.23M | (m) | (m) |
| 2023-09-30 | $-86.16M | (m) | (m) | $72.58M | (m) | (m) |
| 2023-06-30 | $-86.62M | (m) | (m) | $73.18M | (m) | (m) |
| 2023-03-31 | $-88.86M | (m) | (m) | $76.12M | (m) | (m) |
| 2022-12-31 | $-56.76M | (m) | (m) | $44.97M | (m) | (m) |
| 2022-09-30 | $-53.31M | (m) | (m) | $42.00M | (m) | (m) |
| 2022-06-30 | $-50.16M | (m) | (m) | $39.98M | (m) | (m) |
| 2022-03-31 | $-42.89M | (m) | (m) | $33.14M | (m) | (m) |
| 2021-12-31 | $-41.43M | $1.50M | (m) | $32.16M | (m) | -2761.73% |
| 2021-09-30 | $-38.09M | $1.50M | (m) | $29.19M | (m) | -2539.47% |
| 2021-06-30 | $-33.46M | $1.50M | (m) | $24.48M | (m) | -2230.67% |
| 2021-03-31 | $-31.33M | $1.50M | (m) | $22.63M | (m) | -2088.67% |
| 2020-12-31 | $-28.54M | $1.50M | (m) | $20.42M | (m) | -1902.60% |
| 2020-09-30 | $-29.66M | (m) | (m) | $20.99M | (m) | (m) |
| 2020-06-30 | $-30.07M | (m) | (m) | $21.39M | (m) | (m) |
| 2020-03-31 | $-31.04M | (m) | (m) | $22.18M | (m) | (m) |
| 2019-12-31 | $-33.45M | (m) | (m) | $24.37M | (m) | (m) |
| 2019-09-30 | $-34.15M | (m) | (m) | $25.61M | (m) | (m) |
| 2019-06-30 | $-34.83M | (m) | (m) | $26.29M | (m) | (m) |
| 2019-03-31 | $-33.20M | (m) | (m) | $24.39M | (m) | (m) |
| 2018-12-31 | $-30.75M | (m) | (m) | $21.83M | (m) | (m) |
| 2018-09-30 | $-28.33M | (m) | (m) | $19.34M | (m) | (m) |
| 2018-06-30 | $-28.31M | (m) | (m) | $19.68M | (m) | (m) |
| 2018-03-31 | $-28.49M | (m) | (m) | $20.33M | (m) | (m) |
| 2017-12-31 | $-32.35M | (m) | (m) | $22.50M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-27.30M | (m) | (m) | $23.29M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |